EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0QZU: Vertex Pharmaceuticals Inc.

26 Nov 2025
LAST:

430.7

CHANGE:
 1.65		OPEN:
430.1		HIGH:
432.7		ASK:
0.0		VOLUME:
310
CHG(%):
0.38		PREV:
429.0		LOW:
427.4		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Nov 25430.1432.7427.4430.7310
25 Nov 25424.0430.6420.6429.0502
24 Nov 25426.8432.4423.7427.2443
21 Nov 25422.7433.8419.5432.0200
20 Nov 25420.1430.5416.9427.3199
19 Nov 25439.1439.1421.3421.31.4K
18 Nov 25435.3437.9430.0436.8421
17 Nov 25436.5439.3432.2433.7100
14 Nov 25437.5442.0435.5439.7140
13 Nov 25435.0441.1430.7434.9452

PROFILE

Name:Vertex Pharmaceuticals Inc.
About:Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Address:50 Northern Avenue, Boston, MA, United States, 02210
Website:https://www.vrtx.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.44 
Price to Sales:9.39 
Price to Book:6.53 
Profit Margin:0.32 
Operating Margin:0.39 
Return on Assets:0.13 
Return on Equity:0.23 
EPS Ratio:9.48 
Revenue:11.419B 
EBITDA:294.71M 
Shares:255.56M 
Market Cap:110.064B 

TECHNICAL INDICATORS

MA5:429.240.3%
MA10:431.270.1%
MA20:426.311.0%
MA50:413.874.1%
MA100:416.633.4%
MA200:442.732.8%
STO9:45.26
STO14:66.20
RSI14:58.89
WPR14:-28.94
MTM14:22.15
ROC14:0.05 
ATR:10.16 
Week High:439.102.0%
Week Low:416.893.3%
Month High:441.992.6%
Month Low:403.572.8%
Year High:519.6820.7%
Year Low:117.44266.7%
Volatility:7.76 

RECENT DIVIDENDS

Date Amount
06 Sep 2022$0.04
24 May 2022$0.07
31 Aug 2021$0.04
18 May 2021$0.07
17 May 2021$0.07
01 Sep 2020$0.03
19 May 2020$0.10
03 Sep 2019$0.06
21 May 2019$0.13
04 Sep 2018$0.07